XNYS
COP
Market cap163bUSD
Oct 08, Last price
134.19USD
1D
3.35%
1Q
23.06%
Jan 2017
167.63%
Name
Conocophillips
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
CompuGroup Medical SE & Co. KGaA (CGM) is a global developer and vendor of sophisticated information technology and software solutions tailored for the healthcare industry. The company organizes its diverse offerings into four primary operational segments: Ambulatory Information Systems (AIS): This segment furnishes physicians, medical centers, and professional networks with essential practice management software and electronic medical records. It also provides complementary internet and intranet-based tools to support outpatient care. Pharmacy Information Systems (PCS): Focusing on the pharmaceutical sector, PCS delivers administrative and billing software applications designed for pharmacies. These solutions offer critical information and decision-making support for managing the intricate medication supply chain. Hospital Information Systems (HIS): Catering to the inpatient environment, this segment provides comprehensive clinical and administrative solutions. Its clientele includes acute care hospitals, rehabilitation facilities, social service organizations, multi-site hospital networks, regional care providers, and medical laboratories. Consumer & Health Management Information Systems (CHS): This broad segment encompasses services such as IT security, data-driven product suites, interfaces for information exchange, clinical decision support tools, and extensive medication and treatment databases for healthcare service providers. Additionally, it develops digital healthcare platforms, consumer portals, and mobile applications, along with security measures for providers. Its customer base is expansive, covering pharmaceutical companies, health insurance providers, other healthcare IT firms, and direct consumers. Founded in 1987 and headquartered in Koblenz, Germany, the company officially adopted its current designation, CompuGroup Medical SE & Co. KGaA, in June 2020, having previously operated as CompuGroup Medical SE.
Related entities
Subsidiaries (15)
Conoco Petroleum Operations Inc.
CONOCOPHILLIPS (U.K.) MARKETING AND TRADING LIMITED
CONOCOPHILLIPS ARGENTINA VENTURES S R L
CONOCOPHILLIPS ASIA VENTURES PTE. LTD.
CONOCOPHILLIPS FUNDING LTD.
CONOCOPHILLIPS SKANDINAVIA AS
CONOCOPHILLIPS (U.K.) HOLDINGS LIMITED
CONOCOPHILLIPS ALASKA, INC.
CONOCOPHILLIPS ANS MARKETING COMPANY
CONOCOPHILLIPS CANADA MARKETING & TRADING ULC
CONOCOPHILLIPS CANADA RESOURCES CORP.
CONOCOPHILLIPS COMPANY
CONOCOPHILLIPS MARKETING B.V.
CONOCOPHILLIPS TREASURY LIMITED
Rodeo Insurance Company
Key people
Andrew O'Brien
Chief Financial Officer · since 2025
Nicholas Olds
Executive Vice President - Lower 48 · since 2022
Heather Hrap
Senior Vice President - Human Resources and Real Estate and Facilities Services · since 2022
Kirk Johnson
Senior Vice President - Global Operations · since 2024
Andrew Lundquist
Senior Vice President - Government Affairs · since 2013
Kelly Rose
Senior Vice President, Legal, General Counsel, Company Secretary · since 2018
Kontessa Hayneswelsh
Vice President, Controller · since 2025
Glenda Schwarz
Vice President, Treasurer · since 2019
Philip Gresh
Vice President - Investor Relations, Treasurer · since 2025
Lead Independent Director · since 2019
Chairman of the Board, Chief Executive Officer · since 2012
Director, Advisor to the Chief Executive Officer · since 2022
Independent Director · since 2022
Nelda Connors
Independent Director · since 2024
Gay Evans
Independent Director · since 2013
Independent Director · since 2018
Kathleen Mcginty
Independent Director · since 2025
William Mcraven
Independent Director · since 2018
Sharmila Mulligan
Independent Director · since 2017
Independent Director · since 2015
Legal address
C/O CORPORATION SERVICE COMPANY
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
925 North Eldridge Parkway
Houston, TX 77079
US
Houston, TX 77079
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||